Pharmaceuticals Anonymous

Showing posts with label elder abuse. Show all posts
Showing posts with label elder abuse. Show all posts

Wednesday, October 7, 2009

UK: Scandalous abuse of the elderly - prescribed antipsychotics

From the page:
It is the first time the scale of the abuse in hospital wards is exposed, following warnings that 100,000 dementia patients in care homes are prescribed the drugs leading to the deaths of 23,000 a year

Three quarters of nurses have seen people with dementia in general wards in hospital prescribed antipsychotic drugs that are known to double the risk of death and triple the risk of a stroke in these patients, research has shown.

It is the first time the scale of the abuse in hospital wards is exposed, following warnings that 100,000 dementia patients in care homes are prescribed the drugs leading to the deaths of 23,000 a year.

Ten leading charities, carers groups and experts have written to The Daily Telegraph saying: "We cannot stand by while this scandalous abuse of vulnerable citizens continues."

Neil Hunt, Chief Executive of Alzheimer’s Society said: "The massive over prescription of antipsychotics to people with dementia is an abuse of human rights, causing serious side effects and increasing risk of death. These powerful drugs should only be used in a small number of cases. The Government must take action to ensure that these drugs are only ever used as a last resort."

They have called on the government to publish its long-overdue review of the use of antipsychotics which ministers promised would be out in May of this year.

Rebecca Wood, Chief Executive of the Alzheimer’s Research Trust, said: "While the Department of Health prevaricates, thousands of people are being put at risk through the misuse of antipsychotics."

There are 700,000 people in Britain with dementia and the numbers are rising rapidly.
Antipsychotics have a sedative effect and are not licensed for use in dementia but are prescribed when patients become agitated or difficult and often then are left on them for long periods.


Link

Thursday, October 1, 2009

Drug-Induced Dementia: The Perfect Crime

"Under the influence of declining birth rates, expanding longevity, and changing population structures around the world, the global prevalence of senile dementia is expected to increase more than four-fold within the next forty years. Within the United States alone, the number of affected individuals over the age of 65 is expected to rise exponentially from 8 million cases (2% of the entire population in the year 2000), to 18 million retirees (roughly 4.5% of the national census in the year 2040). Although they are striking, these statistics quite likely underestimate the scope of the coming epidemic, as they fail to consider the impact of under-diagnosis, early-onset disease, and the potential for a changing incidence of illness in the context of increasingly toxic environments.

In the face of this imminent crisis, concerned observers have called for policies and practices which aim to prevent, limit, or reverse dementia. Drug-Induced Dementia: A Perfect Crime is a timely resource which reveals why and how medical treatments themselves – specifically, psychopharmaceuticals – are a substantial cause of brain degeneration and premature death.

A first-of-its-kind resource for patients and clinicians, the book integrates research findings from epidemiology (observational studies of patients in the “real world”), basic biology (animal experiments), and clinical science (neuroimaging and autopsy studies) in order to demonstrate the dementing and deadly effects of psychiatric drugs.

Highlighted by more than 100 neuroimages, slides of tissue specimens, and illustrations, the book uniquely describes:

Ø the societal roots of the problem
(target organ toxicity, regulatory incompetence, and performativity)

Ø the subtypes and essential causes of dementia

Ø the patterns, prevalence, and causes of dementia associated with antidepressants, antipsychotics, anxiolytics, mood stabilizers, and stimulants

and

Ø the actions and reforms which patients, providers, and policy makers might immediately pursue, in an effort to mitigate the causes and consequences of this iatrogenic tragedy."

Link

Saturday, September 12, 2009

Haldol... and an elderly patient - by Gwen Olsen, author of Confessions of an Rx Pusher

Written by a former top drug company representative - drug seller.
It was the end of the third quarter, and I was behind in my sales quota for Haldol. That meant forfeiting a significant amount of money from the bonus pool if I didn't make quota. My territory was at somewhat of a disadvantage because I didn't have the large number of psychiatrists the reps in other metropolitan areas such as Dallas, Houston, and Austin had. It occurred to me that the most common drawback/objection I received from the general practitioners I called on with this product was patient compliance. (Patients would frequently discontinue the medication because of its side effects.) So, I determined the best way to build my Haldol business would be to campaign for the institutionalized patient. These patients were not only encouraged to take the medication; they were actually given the drug. This completely eliminated the compliance issue.

I set about scheduling training in-services in the local nursing homes and mental health and mental retardation (MHMR) facilities. I increased my call frequency on physicians whom I knew to have nursing home relationships and directorship responsibilities. I littered these offices and institutions with every type of marketing tool known to man. You could not look anywhere in my territory that there wasn't a clock, coffee mug, calendar, candy dish, scratch pad, or pen displaying the Haldol name.

During my so-called "Haldol Blitz," I made weekly visits to my nursing homes. The nursing staff was very supportive and appreciated being the recipients of all the goodies and attention that was rarely placed on them. (Reps notoriously do not like to call on nursing homes or abortion clinics.) They began to eagerly recommend to doctors that patients be placed on Haldol and actually kept track of patients who were put on the drug to report to me on subsequent visits. I rewarded these facilities and staffs with catered-in lunches and gift certificatesto local restaurants.

In my routine visits to one particular nursing home, I met Mrs. Ida Smith. (I have changed her name to protect her privacy.) Mrs. Smith was a petite, fragilelooking woman in her late eighties. Her snow-white hair was always neatly coiffed. She also wore a bright red lipstick that contrasted starkly with her delicate, pale complexion. Ida was a whirlwind of activity in her motorized wheelchair. She was frequently seen motoring from room to room, checking on and visiting with other residents. It was apparent the nursing staff was put out with Mrs. Smith's meddling. Ida often complained to staff about patients who were not properly being cared for. She was the self-appointed hall monitor and was not afraid to let people know she was watching. I got a kick out of observing the nurses' reactions when Mrs. Smith would demand someone change a bedpan or IV bag that had been left unattended. She could definitely hold her own in a debate.

Mrs. Smith became a bright spot in my visits to an otherwise gloomy, depressing facility that reeked with the stench of urine and disinfectant. However, I called on the home one day, and Mrs. Smith was nowhere to be seen. Before departing, I questioned the head nurse about her. "Oh, Mrs. Smith, she's had a bad patch lately," she said. "Her friend in 17B died, and it really upset her. She hadn't been sleeping well and seemed a little disoriented, so we recommended her doctor put her on Haldol. She's doing a lot better now...sleeping through the night...not combative and quarrelsome like she used to be." She concluded, smiling.(It was obvious she thought she was making brownie points with me.)

As I rounded the corner to the front door, I saw an attendant pushing Mrs. Smith in her wheelchair into her room. Her head was hung, and she was drooling on her pretty, pink gown. Mrs. Smith looked like a zombie. She was in complete disarray. Her hair was uncombed, and her signature red lipstick was missing. I felt a pang in the pit of my stomach. Had I been responsible for this turn of events? Surely, Mrs. Smith was not the patient-type for whom I had promoted Haldol. Or was she?

I exceeded my quota in all four of my products that sales quarter. Shortly thereafter, I was promoted to a hospital rep's position in Houston for the Baylor College of Medicine. I would never see Mrs. Smith again. However, my last memory of her would stay fresh in my mind and on my conscience for many years to come.


Link

Tuesday, February 3, 2009

Alzheimer's and B3/Niacin


Vitamin B3/Niacin as Alzheimer's therapy:
"Memory loss is the signature feature of Alzheimer's disease, and therapies that prevent or delay its onset are urgently needed. Effective preventive strategies likely offer the greatest and most widespread benefits. Histone deacetylase (HDAC) inhibitors increase histone acetylation and enhance memory and synaptic plasticity. We evaluated the efficacy of nicotinamide, a competitive inhibitor of the sirtuins or class III NAD+-dependent HDACs in 3xTg-AD mice, and found that it restored cognitive deficits associated with pathology. Nicotinamide selectively reduces a specific phospho-species of tau (Thr231) that is associated with microtubule depolymerization, in a manner similar to inhibition of SirT1. Nicotinamide also dramatically increased acetylated -tubulin, a primary substrate of SirT2, and MAP2c, both of which are linked to increased microtubule stability. Reduced phosphoThr231-tau was related to a reduction of monoubiquitin-conjugated tau, suggesting that this posttranslationally modified form of tau may be rapidly degraded. Overexpression of a Thr231-phospho-mimic tau in vitro increased clearance and decreased accumulation of tau compared with wild-type tau. These preclinical findings suggest that oral nicotinamide may represent a safe treatment for AD and other tauopathies, and that phosphorylation of tau at Thr231 may regulate tau stability."
Link
More here: Link
A link has been established between Alzheimer's and calcium - a substance we take like candy in antacids. Link
What is the counterbalance for calcium? Magnesium. What makes magnesium work better? Niacin....